Perioperative medicine & outcomes

Association Between Neuromuscular Blockade and Its Reversal With Postoperative Delirium in Older Patients: A Hospital Registry Study

Anesth AnalgPublished Retrospective cohort study

Authors' conclusion

Neuromuscular blockade during general anesthesia is dose-dependently associated with a higher risk of postoperative delirium. The administration of reversal agents mitigates this risk

Study context

Population
Adult hospitalised patients aged ≥60 years undergoing GA for noncardiac, nonneurosurgical, nontransplant procedures, Massachusetts, 2008–2024
Participants
53,772 participants
Exposure
Intraoperative ND-NMBA administration vs none
  • ND-NMBAn = 43,723
Outcome
Delirium (chart keyword search with manual review, CAM assessments, ICD codes)
Follow-up
7 days
Methodological detailshospital registry, tertiary health care network
  • Hospital registry
  • Tertiary health care network

Main finding

As reported in the abstract

Adjusted odds ratio (95% CI)P value
ND-NMBA vs No ND-NMBA
1.15(1.01–1.31)
P = 0.038
ND-NMBAper unit increase in ED95 dose
1.09(1.06–1.12)
P < 0.001

Observational data: associations, not effects.

Further findings

OutcomeaOR (95% CI)P value
Impaired neuromuscular recovery (preextubation TOFR <95), reversal vs no reversal38,143 (87.2%) ND-NMBA patients received reversal0.60 (0.49–0.74)P < 0.001
Delirium, reversal vs no reversal0.73 (0.64–0.83)P < 0.001
Delirium, neostigmine vs sugammadex0.91 (0.73–1.12)P = 0.36

Delirium with ND-NMBA, by reversal agent use (subgroup)

aOR (95% CI)P value
ND-NMBA with reversal1.07 (0.94–1.23)P = 0.30
ND-NMBA without reversal1.52 (1.28–1.79)P < 0.001

Original publication

Association Between Neuromuscular Blockade and Its Reversal With Postoperative Delirium in Older Patients: A Hospital Registry Study. Anesth Analg. Published 18 April 2025. doi:10.1213/ane.0000000000007489

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.